Nathalie Franchimont

Nathalie Franchimont is a non-executive Director of OMass Therapeutics. She currently serves as Senior Vice President, Head of Multiple Sclerosis (MS) and Immunology Development Unit at Biogen and is a member of the R&D Leadership Team. Her extensive career in large biotechnology companies (Amgen and Biogen) has spanned drug development from discovery research and target validation through early and late clinical development including multiple filings globally, medical affairs with launch and reimbursement in the international markets. Nathalie is a rheumatologist and trained as an M.D., Ph.D. at the University of Liège, Belgium. She has held research fellowship roles at the University of Connecticut School of Medicine/Saint Francis Hospital (Bone Biology), Yale University School of Medicine (Rheumatology) and University of Liège where she worked as Chief of Clinic and Research Associate (FNRS) in Rheumatology.